Toggle light / dark theme

A new study from the Johns Hopkins University School of Medicine shows that selectively removing senescent cells—cells that no longer divide—from brains with a form of Alzheimer’s disease can reduce brain damage and inflammation and slow the pace of cognitive decline. These findings, say researchers, add to evidence that senescent cells contribute to the damage caused by Alzheimer’s disease.

“Our results show that eliminating these cells may be a viable route to treat Alzheimer’s disease in humans,” says Mark Mattson, a professor of neuroscience at the School of Medicine and a senior investigator in the Laboratory of Neurosciences at the National Institute on Aging.

A report on the work was published April 1 in Nature Neuroscience.

With ageing, intrinsic haematopoietic stem cell (HSC) activity decreases, resulting in impaired tissue homeostasis, reduced engraftment following transplantation and increased susceptibility to diseases. However, whether ageing also affects the HSC niche, and thereby impairs its capacity to support HSC function, is still widely debated. Here, by using in-vivo long-term label-retention assays we demonstrate that aged label-retaining HSCs, which are, in old mice, the most quiescent HSC subpopulation with the highest regenerative capacity and cellular polarity, reside predominantly in perisinusoidal niches. Furthermore, we demonstrate that sinusoidal niches are uniquely preserved in shape, morphology and number on ageing. Finally, we show that myeloablative chemotherapy can selectively disrupt aged sinusoidal niches in the long term, which is linked to the lack of recovery of endothelial Jag2 at sinusoids. Overall, our data characterize the functional alterations of the aged HSC niche and unveil that perisinusoidal niches are uniquely preserved and thereby protect HSCs from ageing.

Researchers at the Spanish National Cancer Research Centre (CNIO) have shown that it is possible to extend the life of mice, without using any gene modifying technologies. The finding is the result of a study launched some years ago that aimed to investigate mice with hyper-long telomeres.

Chromosome

51-year-old astronaut Scott Kelly lived in the International Space Station for almost a year while his identical twin brother Mark continued with life on earth. As an astronaut, Scott is a member of group that’s been studied in greater depth than any other living humans. As part of a special study, so was his earthbound twin.

The many negatives of space travel were expected to take their toll on Scott’s health — and they did.

Metabesity 2019: Epigenetic resetting of cellular age mediated by nuclear reprogramming – A new paradigm in overcoming aging and aging-associated diseases.
Featuring Vittorio Sebastiano, PhD, Assistant Professor of Stanford University; Co-Founder of Turn Biotechnologies, USA

For more information, see www.metabesity2019.com

The scene last weekend at the Westgate, a Las Vegas mega resort, was like many others in Sin City. Alongside the one-armed bandits and craps tables, around 1,000 people milled around a mega convention centre. Many would have been close to pensionable age, and came from all corners of the Earth. But all the attendees at the event, RAADfest, were pursuing something out of the ordinary: immortality.


‘Immortalists’ say they have discovered how to slow and perhaps even reverse the ageing process — but is that really a good thing?

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Sree Kant of Life Biosciences discussed investment and R&D in an aging world, demonstrating the necessity of rejuvenation biotechnology in keeping people over the age of 65 healthy and productive. He showed that we need effective treatments for the root causes of aging rather than just downstream conditions, bringing up the necessity of a broad rejuvenation ecosystem that uses VC and other investment to fund companies that focus on these root causes.

This is a clip from a conversation with Michio Kaku from Oct 2019. New full episodes once or twice a week and 1-2 new clips or a new non-podcast video on all other days. You can watch the full conversation here: https://www.youtube.com/watch?v=kD5yc1LQrpQ
(more links below)

Podcast full episodes playlist:

Podcasts clips playlist:

Podcast website:

Artificial Intelligence: AI Podcast

Podcast on Apple Podcasts (iTunes):
https://apple.co/2lwqZIr

Podcast on Spotify:
https://spoti.fi/2nEwCF8